GUEST COLUMNISTS

• These Four Things Are Helping Minovia Therapeutics' Rare Disease Trials

  Minovia Therapeutics shares the importance of careful site selection, specialized operational expertise, multidisciplinary collaboration, and innovative trial design as it prepares for pivotal this year.

• Heard At SCOPE: Pharma Wants ROI For Patient Data Return, Diverse Enrollment

  Twice I heard “ROI is the elephant in the room.” Two different panel discussions, two different tracks. 

• What ChatGPT Ads Will Really Mean For Clinical Trials

  AI health assistants may be used to surface clinical trials earlier in patient journeys, and advertising inside conversational AI is best understood as the next logical step in that same progression.

• The FDA Calls For Culturally-Informed Research, But What Do We Understand About The Sikh Community?

  Despite the size and visibility of the community — and the call for diverse patient research — there remains a gap in available health data specific to the Sikh community in the U.S.

• The Key Role Of Clinical Supply Teams In Patient Centricity Efforts

  Clinical supply decisions shape patient access, safety, and trial success. From logistics to procurement, patient-centric supply can accelerate therapies or quietly delay them.

• Pharma Procurement Can Make Or Break Startups: Let's Help Mature Our Future Partners To Secure Innovation

  To secure long-term innovation, Ascendis Pharma's Ivanna Rosendal suggests pharma companies should help startup companies through their growing pains.

• Becoming A Backbone Therapy: Lessons Learned With Actuate Therapeutics

  CEO Dan Schmitt discusses the pursuit of a backbone therapy and how Actuate's current and planned trials are structured to confirm that potential.

• Building Patient Trust In Research Through Connection Driven-Transparency

  The question is not whether trust matters but how industry, sponsors, and investigators can bridge the trust gap to drive patient participation.